Hangzhou Alltest Biotech Co., Ltd.

Shanghai Stock Exchange 688606.SS

Hangzhou Alltest Biotech Co., Ltd. Revenue Per Share for the year ending December 31, 2023: USD 1.34

Hangzhou Alltest Biotech Co., Ltd. Revenue Per Share is USD 1.34 for the year ending December 31, 2023, a -78.61% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

Hangzhou Alltest Biotech Co., Ltd. Revenue Per Share for the year ending December 31, 2022 was USD 6.28, a 69.81% change year over year.
Hangzhou Alltest Biotech Co., Ltd. Revenue Per Share for the year ending December 31, 2021 was USD 3.70, a 69.48% change year over year.
Hangzhou Alltest Biotech Co., Ltd. Revenue Per Share for the year ending December 31, 2020 was USD 2.18, a 401.99% change year over year.
Hangzhou Alltest Biotech Co., Ltd. Revenue Per Share for the year ending December 31, 2019 was USD 0.43, a -36.00% change year over year.

Key data

Date	Revenue Per Share	Dividend Per Share	Free Cash Flow Per Share	Return on Assets (ROA)

Shanghai Stock Exchange: 688606.SS

Hangzhou Alltest Biotech Co., Ltd.

CEO	Mr. Fei Gao
IPO Date	March 25, 2021
Location	China
Headquarters	#550, Yinhai Street
Employees	1,093
Sector	Health Care
Industries Biotechnology Chemicals & Advanced Materials Pharmaceuticals

Description

Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and market of in vitro diagnostic reagents worldwide. It offers rapid diagnostic products, including women's health, infectious diseases, drugs, cancer, cardiovascular, and other five series of products. The company is based in Hangzhou, China.

Key trends

Past 5 years